Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:d76048bf981b937fe4b835e79052f471]
Assessment of graft function
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Lowest dose that will allow at least an 80% decrease in the activity of classic pathway and MBL pathway of complement in brain death donors with KDPI over 85%, with the purpose of reducing the incidence of delayed graft function. over a 12 month period [clinicaltrials_resource:d76048bf981b937fe4b835e79052f471]
Assessment of graft function
Bio2RDF identifier
d76048bf981b937fe4b835e79052f471
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d76048bf981b937fe4b835e79052f471
measure [clinicaltrials_vocabulary:measure]
Lowest dose that will allow at ...... nce of delayed graft function.
time frame [clinicaltrials_vocabulary:time-frame]
over a 12 month period
description
Assessment of graft function
identifier
clinicaltrials_resource:d76048bf981b937fe4b835e79052f471
title
Lowest dose that will allow at ...... nction. over a 12 month period
@en
type
label
Lowest dose that will allow at ...... 048bf981b937fe4b835e79052f471]
@en